Regulatory requirements are always there in black and white. Prana has the options to circumvent those roadblocks. FDA is actually nice allowing Prana to complete several human trials first to collect supporting data. If Prana failed in commercializing PBT2 finally, they could only blame themselves.
Regulatory requirements are always there in black and white....
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $1.247K | 384.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 52935756 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 127950526 | 19 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |